Jiangsu Hengrui Medicine Co Ltd (Jiangsu Hengrui) focuses on the research, development, manufacture and distribution of novel pharmaceutical products for treating cancer, diabetes, Crohn’s disease, psoriasis and other diseases.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company's R&D focuses on discovering new products and enhancing its existing products. It focuses on developing generic drugs, high activity, hormones, and contrast agents It has R&D facilities in Shanghai, Lianyungang, Chengdu, China, Japan, and the US. It also operates a clinical medical center in Shanghai. In FY2022, the company submitted 169 new domestic and international patent applications. The company owns 2064 patents, 583 PCT patents, 507 domestic valid authorized invention patents. It submitted 89 applications, 147 domestic authorizations and 140 foreign authorization. In FY2022, the company spent CNY4,886.6 million on R&D, which as a percentage of revenue stood at 23%. It has more than 5,015 people working towards its R&D activities.